Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET.
2024年6月5日，馬薩諸塞州沃思姆（WALTHAM） - Apellis Pharmaceuticals, Inc.（納斯達克：APLS）今天宣佈公司將於2024年6月12日星期三下午4:00在高盛第45屆全球醫療保健大會上舉辦爐邊聊天。
The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event.
直播會議網絡研討會將發佈在公司“投資者和媒體”部分的“活動和演示文稿”頁面上。網絡研討會的重播將在活動結束後的90天左右提供。網站關於Apellis Pharmaceuticals：Apellis Pharmaceuticals, Inc.是一家全球性生物製藥公司，融合了勇氣科學和同情心，爲一些患者面臨的最具挑戰性的疾病開發改變生命的療法。我們引進了15年來的第一類新的互補醫學，並已經獲得兩個批准的藥物，針對C3。這些包括全球最主要致盲病因之一的地理性萎縮的第一個療法。我們認爲，我們只是開始解鎖針對C3治療嚴重的視網膜，罕見疾病和神經系統疾病的潛力。欲知更多信息，請訪問http://apellis.com。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
關於Apellis
Apellis Pharmaceuticals, Inc.是一家全球性生物製藥公司，融合了勇氣科學和同情心，爲一些患者面臨的最具挑戰性的疾病開發改變生命的療法。我們引進了15年來的第一類新的互補醫學，並已經獲得兩個批准的藥物，針對C3。這些包括全球最主要致盲病因之一的地理性萎縮的第一個療法。我們認爲，我們只是開始解鎖針對C3治療嚴重的視網膜，罕見疾病和神經系統疾病的潛力。http://apellis.com或關注我們的推特和頁面。LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投資者聯繫人：
Meredith Kaya
meredith.kaya@apellis.com617.599.8178
譯文內容由第三人軟體翻譯。